Next Article in Journal
4,6,8-Triarylquinoline-3-carbaldehyde Derivatives: Synthesis and Photophysical Properties
Previous Article in Journal
Crystal Structures and Antifungal Activities of Fluorine-Containing Thioureido Complexes with Nickel(II)
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 18
Issue 12
10.3390/molecules181215750
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Design, Synthesis and Evaluation of N13-Substituted Evodiamine Derivatives against Human Cancer Cell Lines

by
Senchuan Song
1,
Zhiyong Chen
1,
Shaoxue Li
1,
Yanmin Huang
2,
Yiqian Wan
1,* and
Huacan Song
1,*
1
School of Chemistry and Chemical Engineering, Sun Yat-sen University, Guangzhou 510275, China
2
College of Chemistry and Life Science, Guangxi Teachers Education University, Nanning 530001, China
*
Authors to whom correspondence should be addressed.
Molecules 2013, 18(12), 15750-15768; https://doi.org/10.3390/molecules181215750
Submission received: 23 October 2013 / Revised: 7 November 2013 / Accepted: 12 November 2013 / Published: 17 December 2013
Browse Figures
Versions Notes

Abstract

:
Attempting to improve the anticancer activity and solubility of evodiamine in simulated gastric fluid (SGF) and simulated intestinal fluid (SIF) solutions, thirty-eight N13-substituted evodiamine derivatives were designed, synthesized and tested for antitumor activities against six kinds of human cancer cell lines, namely prostate cancer (DU-145 and PC-3), lung cancer (H460), breast cancer (MCF-7), colon cancer (HCT-5) and glioblastoma (SF-268). The solubility of these compounds in SGF and SIF solutions was evaluated, and apoptosis induced by 2-2, 2-3, 2-16 and 3-2 was determined. The results showed: (1) among all compounds examined, 2-16 showed the highest antitumor activity and a broader spectrum of activity, with IC50 values ranging from 1–2 µM; (2) their solubility was obviously improved; (3) 2-3, 2-16 and 3-2 had a significant impact inducing apoptosis in some cancer cell lines. The preliminary structure-activity relationships of these derivatives were discussed.

1. Introduction

Evodiamine (1, Figure 1) is a quinolone alkaloid isolated from the fruit of Evodia rutaecarpa (Chinese name: Wu-Chu-Yu), which is one of the most popular and multi-purpose Traditional Chinese Medicines widely used for treating diverse human disorders [1] and is also very attractive as a component of healthy foods [2,3]. It was demonstrated by Hu [4] and Linag [1] that evodiamine possesses a wide range of biological activities related to anti-inflammatory, anti-obesity and antitumor properties. In particular, both the strong cytotoxicity of evodiamine against human cancer cells and the underlining mechanisms of growth inhibition, apoptosis induction and suppression of invasion and metastasis have attracted much attention [4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22]. Moreover, it was demonstrated that evodiamine sensitized chemoresistant breast cancer cells to adriamycin without obvious cytotoxicity against normal human peripheral blood cells [4,23], which indicated the potential of evodiamine for clinical application. In 2010, Sheng and his co-workers identified N13-substituted evodiamine derivatives to be potent topoisomerase I inhibitors by structure-based virtual screening and lead optimization [13]. Recently, the same group has constructed a library of new evodiamine derivatives bearing various substitutions or modified scaffold with substantially increased antitumor activity, which is attributable to the inhibition effect on topoisomerase I and II [16]. Despite its promosing anticancer potential, evodiamine is still unsuitable for clinical application because of its poor physicochemical properties.
Molecules 18 15750 g001 550
Figure 1. Chemical structures of evodiamine (1).
Figure 1. Chemical structures of evodiamine (1).
Molecules 18 15750 g001
In this study, we were interested in using evodiamine as a lead compound to develop anticancer drug candidates, because of its: (1) known broad-spectrum antitumor activities; (2) significant difference of toxicity between cancer cells and normal peripheral blood mononuclear cells; (3) good drug-like molecule features as judged by both the criteria of Lipinski’s “rule of five” and the “verb rule”; (4) good synthetic accessibility for its diversity of derivatives. In our continuous search for novel improved antitumor agents [24,25,26,27,28,29], we report herein the design, synthesis and testing of novel N13-substituted evodiamine derivatives as antitumor agents.

2. Results and Discussion

2.1. Synthesis of N13-Substituted Evodiamine Derivatives

The synthetic pathways to the target compounds are outlined in Scheme 1, Scheme 2, Scheme 3 and Scheme 4. The substitution reactions of evodiamine with alkyl halides or p-toluenesulfonic acid ester at the N13-position of evodiamine were completed smoothly in dried N,N-dimethylformaide (DMF) as reported in reference [13] with slight modifications.
Molecules 18 15750 g004 550
Scheme 1. Synthesis of N13-substitued evodiamine derivatives 2-1–2-29 and 3-1–3-3.
Scheme 1. Synthesis of N13-substitued evodiamine derivatives 2-1–2-29 and 3-1–3-3.
Molecules 18 15750 g004
R1 = 2-1, -CH2CH=CH2; 2-2, -(CH2)3CH3; 2-3, -(CH2)4CH3; 2-4, -CH2CH=C(CH3)2; 2-5, -(CH2)7CH3; 2-6, -(CH2)3C6H5; 2-7, -CH2CH(CH3)2; 2-8, -(CH2)2CH(CH3)2; 2-9, -(CH2)3Cl; 2-10, -(CH2)3Br; 2-11, -(CH2)4Cl; 2-12, -(CH2)2O(CH2)2O(CH2)2Cl; 2-13, -CH2COC6H5; 2-14, -(CH2)2OCH3; 2-15, -(CH2)2O(CH2)3CH3; 2-16, -(CH2)4OCH3; 2-17, -(CH2)2O(CH2)2OCH3; 2-18, -CH2CH(OC2H5)2; 2-19, -(CH2)2OCOCH3; 2-20, -(CH2)3OCOCH3; 2-21, -(CH2)2OCOC2H5; 2-22, -(CH2)2CO2C2H5; 2-23, -(CH2)3CO2C2H5; 2-24, (oxiran-2-yl)methyl; 2-25, -(CH2)2OCOCH(CH3)2; 2-26, -(CH2)5Br; 2-27, -CH2CO2CH2C2H5; 2-28, -(CH2)4CO2C2H5; 2-29, -(CH2)5CO2C2H5. R2 = 3-1, -(CH2)5-; 3-2, -(CH2)6-; 3-3, -(CH2)2O(CH2)2O(CH2)2-.
Molecules 18 15750 g005 550
Scheme 2. Synthesis of N13-(hydroxyalkyl)evodiamine derivatives 4-1 and 4-2.
Scheme 2. Synthesis of N13-(hydroxyalkyl)evodiamine derivatives 4-1 and 4-2.
Molecules 18 15750 g005
Molecules 18 15750 g006 550
Scheme 3. Synthesis of 4-(evodiamin-N13-yl)butyric acid 5.
Scheme 3. Synthesis of 4-(evodiamin-N13-yl)butyric acid 5.
Molecules 18 15750 g006
Molecules 18 15750 g007 550
Scheme 4. Synthesis of 6, 6-1–6-2.
Scheme 4. Synthesis of 6, 6-1–6-2.
Molecules 18 15750 g007

2.2. Solubility of Evodiamine Derivatives in SGF and SIF Main Text Paragraph

We aimed to improve the aqueous solubility of evodiamine, subsequently, to promote its pharmacological or pharmacokinetic peculiarity to enhance its therapeutic effects. The solubilities of N13-position evodiamine derivatives in SGF and SIF solutions were evaluated and the results are shown in Table 1.
Table
Table 1. Solubilities and cytotoxicity of N13-substituted evodiamine analogues.
Table 1. Solubilities and cytotoxicity of N13-substituted evodiamine analogues.
Sample2-12-22-32-42-52-62-72-82-92-10
In SGF(µg/mL)60>12060–120603060>110>15060–120Nd
In SIF(µg/mL)175>33432216272.3142.5>310>373322Nd
IC50 *Prostate DU-1452035>3012>30944>30
Prostate PC-310>3011>30825>30>30920
Lung NCl-H4601423>30830123530
Breast MCF-7>301512>3010>30251816>30
Colon HCT-15193017>301030>30>3013>30
CNS SF-268>3035>3010>3011>304>30
Sample2-112-122-132-142-152-162-172-182-192-20
In SGF(µg/mL)98Viscous30–6015–3030–120Viscous60>120>120>120
In SIF(µg/mL)273solid73.7–14741.6–83.174.4–298solid148286308278
IC50 *Prostate DU-145>3017>30>30152.0>30301514
Prostate PC-339>30>30101>3012186
Lung NCl-H46098>30>3091.5>3010129
Breast MCF-71517>30>30>301>30>301510
Colon HCT-152319>30>30141>30>301513
CNS SF-2682010>30>30251.2>3018107
Sample2-212-222-232-242-252-262-272-282-293-1
In SGF(µg/mL)>120>1203020Viscous67.872.989.4Viscous>120
In SIF(µg/mL)>30826571.955.7solid132.3131.5165.9solid>350
IC50 *Prostate DU-1451714>30>30ndndndndnd12
Prostate PC-39815>307957119
Lung NCl-H460121225>30ndndndndnd15
Breast MCF-7171518>30ndndndndnd8
Colon HCT-15151025>3013151130915
CNS SF-26818920>3021111718810
Sample3-23-34-14-2566-16-2Evodiamine
In SGF(µg/mL)>120nd>220nd606060607.5–15
In SIF(µg/mL)>320nd320nd154173.9166.7160.424.8–49.5
IC50 *Prostate DU-14510ndndnd>30>3020>302
Prostate PC-33ndndnd>308101530
Lung NCl-H4605nd25nd2010101012
Breast MCF-76nd15nd30201515>30
Colon HCT-155nd25nd>30121812>30
CNS SF-2683ndndnd>301512153
* The unit of IC50 is micromole/L.
It is interesting that the solubilities of these derivatives were obviously improved when compared to evodiamine. For example, the solubility of evodiamine itself was only 7.5–15 μg/mL and 24.8–49.5 µg/mL in SGF and SIF, respectively, while the solubilities in SGF and SIF for all evodiamine derivatives were nearly two fold that of evodiamine itself.

2.3. Activity of Evodiamine Derivatives against Human Cancer Cell Lines

To evaluate the antiproliferative effects of the evodiamine derivatives on human cancer cells, the derivatives were used to treat a variety of human cancer cell lines derived from prostate cancer (DU-145 and PC-3), lung cancer (NCl-H460), breast cancer (MCF-7), colon cancer (HCT-15) and glioblastoma (SF-268) and the growth inhibition effect was tested by MTT cytotoxicity assays using evodiamine as a reference. The results are listed in Table 1.
We observed that the appropriate substitution on N13-position of evodiamine made the derivatives more cytotoxic (Table 1, compound 2-16, with IC50 less than 2 μM for all six tested cancer cell lines) and broadened antitumor spectra (Table 1, 2-2, 2-16, 3-2, 2-3, 2-5, 2-9, 2-20, 3-1, 3-2, 6-1 and 6-2). While improper substitution on N13-position of evodiamine, (for example, with alkyl groups, Table 1, 2-1, 2-4, and 2-6) resulted in a decrease of antitumor potency. It should be noted that substitution with alkylamino-alkyl groups on the N13-position, as expected, provided us the corresponding derivatives with more solubility in water, but with only moderate antitumor potency (compounds 6-1, 6-2).
Moreover, we tried to make a dimer using a linker between N13-position, as shown in Table 1, which exhibited moderate (compound 3-1) to good (compound 3-2) antitumor activity against all the tested tumor cell lines. It should be very intriguing that the evodiamine derivative with a benzoylmethyl group (Table 1, compound 2-8) was inactive against the six tested tumor cell lines, although it was reported that one with a benzoyl group at N13-position showed higher antitumor activity and broad spectrum activity against A549, MDA-MB-435 and HCT116 [13].

2.4. Analysis of Anticancer Activities by Spatial Three-Dimensional Structures

In order to elucidate the effect of the spatial structure of evodiamine derivatives on anticancer activity, three-dimensional models of evodiamine, N13-(2-methoxyethyl)evodiamine, N13-(2-butoxyethyl)evodiamine, and N13-(4-methoxybubyl)evodiamine were obtained using ChemBioDraw Ultra 11.0 [30] (Figure 2).
Molecules 18 15750 g002 550
Figure 2. Three-dimensional models of evodiamine, N13-(2-methoxyethyl)evodiamine and N13-(2-butoxyethyl)evodiamine and N13-(4-methoxybutyl)evodiamine.
Figure 2. Three-dimensional models of evodiamine, N13-(2-methoxyethyl)evodiamine and N13-(2-butoxyethyl)evodiamine and N13-(4-methoxybutyl)evodiamine.
Molecules 18 15750 g002
Comparing the three-dimensional models of these four compounds, we could not find obvious differences in respect of the spatial three-dimensional structures of the evodiamine moiety, that is, the spatial three-dimensional structure of evodiamine was not changed due to the introduction of alkoxy groups. Therefore, it could be speculated that the reason leading to the difference in the anticancer activities of these four compounds was the differences in the structures of substituents.

2.5. Apoptosis of Human Cancer Cell Lines Induced by Evodiamine Derivatives

The significant difference of antitumor potency resulting from such subtle change in the structures encouraged us to further explore their antitumor mechanism. Hence, compounds 2-2, 2-3, 2-16 and 3-2 were chosen for testing their effect on inducing apoptosis in breast MCF-7, lung NCl-H460 and colon HCT-15 cancer cell lines.
Apoptosis was determined by flow cytometry analysis using the Annexin V-FITC/PI Apoptosis Kit (Becton Dickinson, Franklin Lakes, NJ, USA) and the results are presented in Figure 3 and in Table 2. As shown in Figure 3, compounds 2-3 and 3-2 strongly induced early apoptosis in MCF-7 with the percentages increasing from 3.21% (medium control) to 84.58% and 55.62%, respectively, while 2-16 and 3-2 obviously induced late apoposis in HCT-15 with the percentages increasing from 3.55% (medium control) to 59.01% and 65.67%, respectively. These two compounds also induced late apoptosis in NCl-H460 with a moderate intensity with the percentages increasing to 40%–50%.
Molecules 18 15750 g003 550
Figure 3. Apoposis induced by 2-3 and 3-2 in breast MCF-7 cells.
Figure 3. Apoposis induced by 2-3 and 3-2 in breast MCF-7 cells.
Molecules 18 15750 g003
Table
Table 2. The apoposis results against breast MCF-7, lung NCl-H460 and colon HCT-15 cancer cell lines after 48-hour treatment.
Table 2. The apoposis results against breast MCF-7, lung NCl-H460 and colon HCT-15 cancer cell lines after 48-hour treatment.
Breast MCF-7TreatmentMedium control2-22-32-163-2
Viable cell (%)92.5863.3514.7049.0944.07
Early apoposis (%)3.2134.0084.5847.3855.62
Late apoposis (%)5.212.640.723.530.31
Lung NCl-H460TreatmentMedium control2-22-32-163-2
Viable cell (%)82.6337.8229.2243.7539.89
Early apoposis (%)15.4030.4537.6012.0213.03
Late apoposis (%)1.9831.7333.1744.2347.08
Colon HCT-15TreatmentMedium control2-22-32-163-2
Viable cell (%)91.6167.7172.290.070.73
Early apoposis (%)4.8416.0413.9340.9133.60
Late apoposis (%)3.5516.2613.7659.0165.67

3. Experimental

3.1. General

Evodiamine was purchased from Aladdin Industrial Inc. (Shanghai, China). All the chemicals used were purchased from Guangzhou Chemical Reagent Company (Guangzhou, China), unless otherwise stated. Human cancer cell lines derived from prostate cancer (DU-145 and PC-3), lung cancer (NCl-H460), breast cancer (MCF-7), colon cancer (HCT-15) and glioblastoma (SF-268) were supplied by CK Life Science INT’L. Inc. (Hong Kong, China). The Annexin V-FITC/PI apoptosis Kit was purchased from Becton Dickinson (Franklin Lakes, NJ, USA).
1H-NMR and 13C-NMR spectra were recorded on a Bruker Avance 300 spectrometer (Bruker Company, Saarbrücken, Germany) using CDCl3 or DMSO-d6 as solvent, chemical shifts were given in ppm (δ). Elemental analyses were performed with a Vario EL cube instrument (Elementar Company, Hanau, Germany). The mass spectra were recorded on a LCQ DECA XP LC-MS mass spectrometer (Thermo Company, Waltham, MA, USA) and high resolution mass spectra were recorded on a MAT95XP High Resolution Mass Spectrometer (Thermo Company). X-ray data were collected on a Smart 1000 CCD Single Crystal Diffractometer (Bruker).

3.2. Synthesis of N13-Substituted Evodiamine Derivatives: General Synthetic Procedure for 2-1–2-29

NaH (40% oil, 7.2 mmol) was suspended in a solution of evodiamine (1, 1.82 g, 6.0 mmol) in DMF (30 mL). The mixture was stirred for 20 min, then 7.5 mmol of the appropriate alkylating reagent was added into the mixture, and the reaction mixture was stirred for 8 h more. The mixture was poured into H2O (150 mL) and then extracted with EtOAc. The extract was dried on anhydrous Na2SO4, the EtOAc was removed and the crude product was purified by column chromatography to afford the pure target compounds. The characterization data for these compounds was as follows:
N13-Allylevodiamine (2-1). Colorless solid product 1.49 g, yield 72.4%, m.p. 163–165 °C. 1H-NMR (CDCl3) δ, ppm: 2.43 (s, 3H), 2.91–2.97 (m, 1H), 3.01–3.03 (m, 1H), 3.16–3.25 (m, 1H), 4.81–4.95 (m, 3H), 4.98–5.08 (m, 2H), 5.10–5.15 (m, 1H), 5.94 (s, 1H), 7.15–7.18 (m, 1H), 7.20 (s, 1H), 7.23–7.25 (m, 1H), 7.27–7.30 (m, 1H), 7.37–7.38 (m, 1H), 7.46–7.52 (m, 1H), 7.62 (d, J = 7.8 Hz, 1H), 8.14 (dd, J1 = 7.8 Hz, J2 = 1.8 Hz, 1H). 13C-NMR (CDCl3) δ, ppm: 20.8, 36.9, 39.7, 46.5, 68.3, 110.2, 113.6, 116.9, 119.2, 120.0, 122.9, 123.3, 124.4, 126.0, 128.6, 129.2, 133.1, 133.6, 133.9, 137.5, 151.0, 164.7. ESI-MS, m/z 344.2 [M+H]+. Anal. Calcd for C22H21N3O: C, 76.94; H, 6.16. Found: C, 77.01; H, 6.21.
N13-Butylevodiamine (2-2). Yellowish solid product 1.25 g, yield 58.0%, m.p. 141–143 °C. 1H-NMR (CDCl3) δ, ppm: 0.96 (t, J = 7.5 Hz, 3H), 1.34–1.46 (m, 2H), 1.77–1.88 (m, 2H), 2.42 (s, 3H), 2.84–2.95 (m, 1H), 3.01–3.07 (m, 1H), 3.15–3.25 (m, 1H), 4.15–4.24 (m, 1H), 4.32–4.42 (m, 1H), 4.88–4.95 (m, 1H ), 5.98 (s, 1H), 7.14–7.17 (m, 1H), 7.19–7.21 (m, 1H), 7.23–7.31 (m, 2H), 7.41 (d, J = 8.1 Hz, 1H), 7.47–7.53 (m, 1H), 7.62 (d, J = 7.8 Hz, 1H), 8.15 (dd, J1 = 7.5 Hz, J2 = 1.5 Hz, 1H). 13C-NMR (CDCl3) δ, ppm: 14.3, 20.9, 32.7, 36.9, 39.7, 44.1, 68.4, 110.0, 110.1, 113.2, 119.2, 119.7, 122.7, 123.3, 124.4, 125.9, 128.6, 129.2, 133.1, 137.4, 151.1, 164.7. HRMS m/z (M+H)+: Calcd for C23H26N3O, 360.2070; found: 360.2084.
N13-Pentylevodiamine (2-3). Yellowish solid product 1.55 g, yield 69.3%, m.p. 143–145 °C. 1H-NMR (CDCl3) δ, ppm: 0.92 (t, J = 7.2 Hz, 3H), 1.37–1.39 (m, 4H), 1.83–1.87 (m, 2H), 2.43 (s, 3H), 2.85–2.96 (m, 1H), 3.02–3.07 (m, 1H), 3.16–3.26 (m, 1H), 4.14–4.24 (m, 1H), 4.31–4.41 (m, 1H), 4.90–4.95 (m, 1H), 5.98 (s, 1H), 7.14–7.22 (m, 2H), 7.24–7.27 (m, 1H), 7.29–7.31 (m, 1H), 7.39–7.41 (m, 1H), 7.48–7.54 (m, 1H), 7.63 (d, J = 7.8 Hz, 1H), 8.13–8.17 (m, 1H). 13C-NMR (CDCl3) δ, ppm: 14.4, 20.8, 22.8, 29.7, 30.3, 36.8, 39.7, 44.4, 68.4, 110.1, 113.2, 119.2, 119.7, 122.7, 123.3, 124.4, 125.9, 128.5, 129.2, 133.1, 137.4, 151.1, 164.7. HRMS m/z (M+H)+: Calcd for C24H28N3O, 374.2227 (M+H)+; found: 374.2238.
N13-(3-Methyl-2-butenyl)evodiamine (2-4). Yellowish viscous solid product 1.01 g, yield 45.4%. 1H-NMR (CDCl3) δ, ppm: 1.68 (d, J = 0.9 Hz, 3H), 1.77 (s, 3H), 2.45 (s, 3H), 2.88–2.96 (m, 1H), 3.00–3.07 (m, 1H), 3.16–3.25 (m, 1H), 4.77–4.84 (m, 1H), 4.88–4.94 (m, 1H), 5.04–5.12 (m, 1H ), 5.20–5.26 (m, 1H ), 5.93 (s, 1H), 7.14–7.17 (m, 1H), 7.19–7.20 (m, 1H), 7.22–7.25 (m, 1H), 7.27–7.30 (m, 1H), 7.35–7.38 (m, 1H), 7.46–7.51 (m, 1H), 7.61 (d, J = 7.5 Hz, 1H), 8.14 (dd, J = 7.5 Hz, 1.5 Hz, 1H). 13C-NMR (CDCl3) δ, ppm: 18.4, 20.8, 25.9, 36.9, 39.7, 42.3, 68.3, 110.0, 113.3, 119.2, 119.7, 120.7, 122.7, 123.2, 124.3, 126.0, 128.5, 129.1, 133.0, 135.0, 137.4, 151.0, 164.8. HRMS m/z (M+H)+: Calcd for C24H26N3O, 372.2070; found: 372.2068.
N13-Octylevodiamine (2-5). Yellowish solid product 1.77 g, yield 71.0%, m.p. 65–67 °C. 1H-NMR (CDCl3) δ, ppm: 0.88 (t, J = 7.5 Hz, 3H), 1.26–1.30 (m, 8H), 1.35–1.39 (m, 2H), 1.78–1.82 (m, 2H), 2.38 (s, 3H), 2.88–2.93 (m, 1H), 2.97–3.05 (m, 1H), 3.11–3.24 (m, 1H), 4.11–4.17 (m, 1H), 4.29–4.39 (m, 1H), 4.87–4.93 (m, 1H), 5.92 (s, 1H), 7.11–7.14 (m, 1H), 7.15–7.18 (m, 1H), 7.21–7.22 (m, 1H), 7.24–7.26 (m, 1H), 7.29–7.33 (m, 1H), 7.43–7.50 (m, 1H), 7.60 (d, J = 7.5 Hz, 1H), 8.15 (d, J = 7.8 Hz, 1H). 13C-NMR (CDCl3) δ, ppm: 14.5, 20.8, 22.9, 23.0, 27.5, 29.6, 30.5, 32.1, 36.8, 39.7, 44.3, 68.4, 110.0, 113.2, 119.2, 119.7, 122.7, 123.2, 124.3, 125.9, 128.5, 129.2, 133.0, 137.3, 151.1, 164.7. HRMS m/z (M+H)+: Calcd for C27H34N3O, 416.2696; found: 416.2696.
N13-(3-Phenylpropyl)evodiamine (2-6). Colorless solid product 1.52 g, yield 60.1%, m.p. 158–160 °C. 1H-NMR (CDCl3) δ, ppm: 2.23–2.25 (m, 2H), 2.38 (s, 3H), 2.69 (t, J = 7.2 Hz, 2H), 2.86–3.06 (m, 1H), 3.13–3.22 (m, 2H), 4.20–4.25 (m, 1H), 4.32–4.42 (m, 1H), 4.86–4.93 (m, 1H), 5.84 (s, 1H), 7.09–7.12 (m, 1H), 7.13–7.16 (m, 3H), 7.18–7.20 (m, 1H), 7.21–7.25 (m, 3H), 7.28–7.31 (m, 2H), 7.46–7.52 (m, 1H), 7.61 (d, J = 8.7 Hz,1H), 8.14 (dd, J = 8.7 Hz, 1.2 Hz, 1H). ESI-MS, m/z 422.2 [M+H]+. Anal. Calcd. for C28H27N3O: C, 79.78; H, 6.46. Found: C, 79.66; H, 6.54.
N13-Isobutylevodiamine (2-7). Yellowish solid product 1.18 g, yield 54.8%, m.p. 154–156 °C. 1H-NMR (CDCl3) δ, ppm: 0.86 (d, J = 6.6 Hz, 3H), 0.98 (d, J = 6.6 Hz, 3H), 2.23–2.32(m, 1H), 2.39 (s, 3H), 2.84–2.95 (m, 1H), 3.01–3.08 (m, 1H), 3.16–3.26 (m, 1H), 4.04–4.11 (m, 1H), 4.16–4.23 (m, 1H), 4.89–4.95 (m, 1H ), 5.99 (s, 1H), 7.13–7.20 (m, 2H), 7.23–7.29 (m, 2H), 7.37–7.40 (m, 1H), 7.47–7.52 (m, 1H), 7.61 (d, J = 7.5 Hz, 1H), 8.13–8.16 (m, 1H). 13C-NMR (CDCl3) δ, ppm: 20.8, 20.9, 29.8, 30.1, 36.7, 39.6, 39.7, 51.7, 68.5, 110.0, 110.5, 113.4, 119.1, 119.7, 122.7, 123.1, 124.2, 125.8, 128.9, 129.2, 133.1, 137.8, 151.1, 164.7. ESI-MS, m/z 360.2 [M+H]+. Anal. Calcd. for C23H25N3O: C, 76.85; H, 7.01. Found: C, 76.76; H, 7.14. 360.2070.
N13-Isopentylevodiamine (2-8). Yellowish solid product 1.10 g, yield 49.2%, mp 108–110 °C. 1H-NMR (CDCl3) δ, ppm: 1.00 (d, J = 6.6 Hz, 3H), 1.03 (d, J = 6.3 Hz, 3H), 1. 67–1.78 (m, 3), 2.42 (s, 3H), 2.89–2.96 (m, 1H), 3.01–3.07 (m, 1H), 3.15–3.25 (m, 1H), 4.14–4.23 (m, 1H), 4.33–4.43 (m, 1H), 4.89–4.95 (m, 1H), 5.97 (s, 1H), 7.14–7.17 (m, 1H), 7.19–7.20 (m, 1H), 7.22–7.26 (m, 1H), 7.27–7.31 (m, 1H), 7.37–7.40 (m, 1H), 7.47–7.53 (m, 1H), 7.62 (d, J = 7.5 Hz, 1H), 8.16 (dd, J1 = 7.8 Hz, J2 =1.5 Hz, 1H). 13C-NMR (CDCl3) δ, ppm: 20.8, 22.9, 23.1, 26.8, 36.9, 39.3, 39.7, 42.8, 68.5, 109.9, 113.1, 119.2, 119.7, 122.7, 123.3, 124.5, 125.9, 128.4, 129.2, 133.1, 137.3, 151.1, 164.7. HRMS m/z (M+H)+: Calcd for C24H28N3O, 374.2227; found: 374.2227.
N13-(3-Chloropropyl)evodiamine (2-9). Yellowish solid product 0.96 g, yield 42.1%, m.p. 118–120 °C. 1H-NMR (CDCl3) δ, ppm: 2.27–2.38 (m, 2H), 2.40 (s, 3H), 2.85–2.96 (m, 1H), 3.01–3.07 (m, 1H), 3.21 (td, J1 = 12.6 Hz, J2 = 3.9 Hz, 1H), 3.51–3.65 (m, 2H), 4.33–4.43 (m, 1H), 4.56–4.65 (m, 1H), 4.89–4.96 (m, 1H), 6.01 (s, 1H), 7.16–7.22 (m, 2H), 7.24–7.33 (m, 2H), 7.43–7.53 (m, 2H), 7.62 (d, J = 7.8 Hz, 1H), 8.15 (dd, J1 = 7.8 Hz, J2 = 1.5 Hz, 1H). 13C-NMR (CDCl3) δ, ppm: 20.7, 33.1, 36.8, 39.6, 41.4, 42.5, 68.4, 109.7, 113.8, 119.3, 120.1, 123.1, 123.5, 124.4, 126.0, 128.6, 129.1, 133.1, 137.5, 151.0, 164.7. HRMS m/z (M+H)+: Calcd for C22H23ClN3O, 380.1524; found 380.1527.
N13-(3-Bromopropyl)evodiamine (2-10). Colorless solid product 1.41 g, yield 55.4%, m.p. 130–132 °C. 1H-NMR (CDCl3) δ, ppm: 2.36–2.48 (s, 5H), 2.86–2.96 (m, 1H), 3.01–3.07 (m, 1H), 3.15–3.25 (m, 1H), 3.37–3.47 (m, 2H), 4.32–4.42 (m, 1H), 4.55–4.65 (m, 1H), 4.89–4.95 (m, 1H ), 5.94 (s, 0.16 H), 6.02 (s, 0.84H), 7.16–7.20 (m, 1H), 7.21–7.22 (m, 1H), 7.24–7.28 (m, 1H), 7.30–7.36 (m, 1H), 7.44–7.53 (m, 2H), 7.62 (d, J = 7.8 Hz, 1H), 8.15 (dd, J1 = 7.8 Hz, J2 =1.5 Hz, 1H). 13C-NMR (CDCl3) δ, ppm: 20.8, 30.8, 33.3, 36.9, 39.6, 42.6, 68.4, 109.9, 113.8, 119.3, 120.1, 123.1, 123.5, 124.4, 124.6, 126.0, 128.6, 129.2, 133.1, 137.5, 151.0, 164.6. HRMS m/z (M+H)+: Calcd for C22H23BrN3O, 424.1019; found: 424.1015.
N13-(4-Chlorobutyl)evodiamine (2-11). Colorless solid product 1.17 g, yield 49.5%, m.p. 127–129 °C. 1H-NMR (CDCl3) δ, ppm: 1.82–1.91 (m, 2H), 2.00–2.10 (m, 2H), 2.42 (s, 3H), 2.85–2.96 (m, 1H), 3.01–3.07 (m, 1H), 3.15–3.25 (m, 1H), 3.50–3.62 (m, 2H), 4.09–4.27 (m, 1H), 4.36–4.46 (m, 1H), 4.89–4.95 (dd, J1 = 12.6 Hz, J2 = 4.8 Hz, 1H), 5.97 (s, 1H), 7.15–7.25 (m, 3H), 7.27–7.32 (m, 1H), 7.38–7.41 (m, 1H), 7.51 (t, J = 7.8 Hz, 1H), 7.62 (d, J = 7.8 Hz, 1H), 8.15 (d, J = 7.8 Hz, 1H). 13C-NMR (CDCl3) δ, ppm: 20.8, 30.8, 33.3, 36.9, 39.6, 42.6, 68.4, 109.9, 113.8, 119.3, 120.1, 123.1, 123.5, 124.4, 124.6, 126.0, 128.6, 129.2, 133.1, 137.5, 151.0, 164.6. HRMS m/z (M+H)+: Calcd for C23H25ClN3O, 394.1681; found: 394.1677.
N13-(2-(2-(2-Chloroethoxy)ethoxy)ethyl)evodiamine (2-12). Colorless solid product 0.87 g, yield 31.3%, m.p. 126–128 °C. 1H-NMR (CDCl3) δ, ppm: 2.34 (s, 3H), 2.82–2.93 (m, 2H), 3.07–3.15 (m, 1H), 3.35–3.37 (m, 3H), 3.39–3.41 (m, 5H), 3.71–3.73 (m, 2H), 4.27–4.33 (m, 1H), 4.63–4.71 (m, 1H ), 4.81–4.87 (m, 1H ), 6.07 (s, 1H), 7.11–7.21 (m, 4H), 7.37 (d, J = 8.1 Hz, 1H), 7.40–7.43 (m, 1H), 7.55 (d, J = 7.8 Hz, 1H), 8.08 (dd, J1 = 7.8 Hz, J2 = 1.2 Hz, 1H). 13C-NMR (CDCl3) δ, ppm: 20.4, 35.5, 39.3, 42.7, 43.8, 67.8, 70.1, 70.6, 70.7, 71.3, 109.8, 113.2, 119.0, 120.1, 122.6, 123.1, 124.2, 124.4, 126.1, 128.9, 129.4, 132.9, 137.2, 151.8, 163.9. HRMS m/z (M+H)+: Calcd for C25H29ClN3O3, 454.1892; found: 454.1905.
N13-(Benzonylmethyl)evodiamine (2-13). Yellowish solid product 0.53 g, yield 21.0%, m.p. 245 °C (decomposed). 1H-NMR (CDCl3) δ, ppm: 2.35 (s, 3H), 2.94–3.00 (m, 1H), 3.06–3.11 (m, 1H), 3.22–3.31 (m, 1H), 4.89–4.95 (m, 1H), 561 (s, 0.23H), 5.67 (s, 1.61H), 5.74 (s, 0.17H), 5.87 (s, 1H), 6.73–6.76 (m, 1H), 7.17–7.24 (m, 3H), 7.27–7.37 (m, 2H), 7.52–7.57 (m, 2H), 7.63–7.70 (m, 2H), 8.07–8.15 (m, 3H). ESI-MS, m/e 422.2 [M+H]+. Anal. Calcd for C27H23N3O2: C, 76.94; H, 5.50. Found: C, 76.96; H, 5.54.
N13-(2-Methoxyethyl)evodiamine (2-14). Colorless solid product 1.31 g, yield 60.5%, m.p. 166–168 °C. 1H-NMR (CDCl3) δ, ppm: 2.37 (s, 3H), 2.73–2.83 (m, 1H), 2.95–2.08 (m, 2H), 3.15 (s, 3H), 3.62 (t, J = 8.1, Hz 2H), 4.40–4.57 (m, 2H), 4.62–4.68 (m, 1H), 6.13 (s, 1H), 7.07 (t, J = 7.5 Hz, 1H), 7.17–7.23 (m, 2H), 7. 31 (d, J = 7.8 Hz, 1H), 7.50–7.57 (m, 3H), 7.92 (d, J = 7.8 Hz, 1H). ESI-MS, m/e 362.2 [M+H]+. Anal. Calcd for C22H23N3O2: C, 73.11; H, 6.41. Found: C, 73.06; H, 6.54.
N13-(2-Butoxyethyl)evodiamine (2-15). Colorless solid product 1.42 g, yield 58.7%, m.p. 68–70 °C. 1H-NMR (CDCl3) δ, ppm: 0.78 (t, J = 7.2 Hz, 3H), 1.14–1.22 (m, 2H), 1.34–1.41 (m, 2H), 2.41 (s, 3H), 2.84–2.94 (m, 1H), 3.00–3.06 (m, 1H), 3.14–3.20 (m, 1H), 3.22–3.30 (m, 1H), 3.32–3.38 (m, 1H), 3.68–3.71 (m, 2H), 4.30–4.38 (m, 1H), 4.65–4.75 (m, 1H), 4.88–4.94 (m, 1H), 6.11 (s, 1H), 7.14–7.17 (m, 1H), 7.19–7.20 (m, 1H), 7.22–7.30 (m, 2H), 7.40–7.43 (m, 1H), 7.46–7.52 (m, 1H), 7.61 (dd, J1 = 7.8 Hz, J2 = 0.9 Hz, 1H), 8.14 (dd, J1 = 7.8 Hz, J2 = 1.2 Hz, 1H). 13C-NMR (CDCl3) δ, ppm: 14.2, 19.5, 20.8, 32.0, 36.8, 39.6, 44.2, 68.3, 69.7, 71.5, 110.0, 113.3, 119.1, 119.8, 122.7, 123.2, 124.2, 124.3, 126.1, 129.1, 129.3, 133.0, 137.4, 151.1, 164.7. HRMS m/z (M+H)+: Calcd for C25H30N3O2, 404.2333; found: 404.2341.
N13-(4-Methoxybutyl)evodiamine (2-16). Yellowish viscous solid product 1.28 g, yield 54.8%. 1H-NMR (CDCl3) δ, ppm: 1.58–1.68 (m, 2H), 1.86–1.96 (m, 2H), 2.41 (s, 3H), 2.84–2.94 (m, 1H), 3.00–3.08 (m, 1H), 3.15–3.23 (m, 1H), 3.25 (s, 3H), 3.37 (t, J = 6.3 Hz, 2H), 4.17–4.48 (m, 1H), 4.38–4.48 (m, 1H), 4.88–4.94 (m, 1H), 5.98 (s, 1H), 7.14–7.18 (m, 1H), 7.18–7.21 (m, 1H), 7.23–7.30 (m, 2H), 7.38–7.41 (m, 1H), 7.46–7.52 (m, 1H), 7.61 (d, J = 7.8 Hz, 1H), 8.15 (dd, J1 = 7.8 Hz, J2 = 1.2 Hz, 1H). 13C-NMR (CDCl3) δ, ppm: 20.8, 27.5, 27.6, 36.8, 39.7, 44.1, 58.9, 68.4, 72.5, 110.0, 113.3, 119.2, 119.7, 122.8, 123.3, 124.2, 124.3, 125.9, 128.5, 129.1, 133.0, 137.3, 151.1, 164.7. ESI-Ms, m/e 404.2 [M+H]+. Anal. Calcd for C24H27N3O2: C, 74.01; H, 6.99. Found: C, 73.96; H, 6.94.
N13-(2-(2-Methoxyethoxy)ethyl)evodiamine (2-17). Colorless solid product 1.73 g, yield 71.2%, m.p. 116–118 °C. 1H-NMR (CDCl3) δ, ppm: 2.41 (s, 3H), 2.83–2.94 (m, 1H), 2.98–3.06 (m, 1H), 3.14–3.21 (m, 1H), 3.23 (s, 3H), 3.35–3.28 (m, 2H), 3.40–3.44 (m, 1H), 3.45–3.52 (m, 1H), 3.71–3.84 (m, 2H), 4.32–4.40 (m, 1H), 4.68–4.78 (m, 1H), 4.88–4.94 (m, 1H), 6.13 (s, 1H), 7.14–7.17 (m, 1H), 7.19 (s, 1H), 7.22–7.26 (m, 1H), 7.27–7.30 (m, 1H), 7.43 (d, J = 8.1 Hz, 1H), 7.49 (td, J1 = 7.5 Hz, J2 = 1.5 Hz, 1H), 7.61 (d, J = 7.8 Hz, 1H), 8.14 (dd, J1 = 7.8 Hz, J2 = 1.8 Hz, 1H). 13C-NMR (CDCl3) δ, ppm: 20.8, 36.8, 39.6, 44.1, 59.3, 68.3, 70.2, 71.0, 72.2, 110.0, 113.4, 119.2, 119.9, 122.8, 123.3, 124.3, 126.1, 128.5, 129.1, 129.3, 133.0, 137.4, 151.1, 164.8. HRMS m/z (M+H)+: Calcd for C24H28N3O3, 406.2125; found: 406.2137.
N13-(2,2-Diethoxyethyl)evodiamine (2-18). Yellowish solid product 0.43 g, yield 18.1%, m.p. 117–119 °C. 1H-NMR (CDCl3) δ, ppm: 0.83 (t, J = 6.9 Hz, 3H), 1.03 (t, J = 6.9 Hz, 3H), 2.35 (s, 3H), 2.72–2.83 (m, 1H), 2.96–3.14 (m, 3H), 3.41–3.52 (m, 2H), 3.59–3.64 (m, 1H), 4.34–4.37 (m, 2H), 4.64–4.73 (m, 2H), 6.18 (s, 1H), 7.05–7.10 (m, 1H), 7.17–7.24 (m, 2H), 7.32 (d, J = 7.8 Hz, 1H), 7.51–7.57 (m, 3H), 7.92 (d, J = 7.8 Hz, 1H). HRMS m/z (M+H)+: Calcd for C25H30N3O3, 420.2282; found 420.2298.
N13-(2-Acetoxyethyl)evodiamine (2-19). Yellowish product 1.22 g, yield 53.8%, m.p. 211–213 °C. 1H-NMR (CDCl3) δ, ppm: 2.03 (s, 3H), 2.39 (s, 3H), 2.73–2.83 (m, 1H), 2.95–3.08 (m, 1H), 3.64–3.69 (m, 2H), 4.30–4.43 (m, 2H), 4.62–4.70 (m, 1H), 4.88–4.92 (m, 1H), 6.20 (s, 1H), 7.11 (d, J = 7.5 Hz, 1H), 7.19–7.25 (m, 2H), 7.33 (d, J = 7.5 Hz, 1H), 7.52–7.60 (m, 3H), 7.94 (d, J = 7.8 Hz, 1H). ESI-MS, m/z 390.2 [M+H]+. Anal. Calcd for C23H23N3O3: C, 70.93; H, 5.95. Found: C, 71.06; H, 6.04.
N13-(3-Acetoxypropyl)evodiamine (2-20). Yellowish viscous product 1.33 g, yield 56.6%. 1H-NMR (CDCl3) δ, ppm: 1.91 (s, 3H), 2.18–2.22 (m, 2H), 2.42 (s, 3H), 2.91–2.96 (m, 1H), 3.03–3.08 (m, 1H), 3.16–3.26 (m, 1H), 4.04–4.10 (m, 1H), 4.15–4.21 (m, 1H), 4.27–4.32 (m, 1H), 4.53–4.58 (m, 1H), 4.90–4.96 (m, 1H), 5.99 (s, 1H), 7.20–7.34 (m, 4H), 7.40–7.43 (m, 1H), 7.50–7.52 (m, 1H), 7.65 (d, J = 7.8 Hz, 1H), 8.17 (d, J = 7.8 Hz, 1H). 13C-NMR (CDCl3) δ, ppm: 20.1, 20.7, 29.2, 36.4, 39.3, 40.6, 61.7, 68.0, 109.5, 113.4, 119.0, 119.8, 122.8, 123.2, 124.1, 124.4, 125.8, 128.3, 129.0, 132.9, 137.1, 150.9, 164.6, 170.9. HRMS m/z (M+H)+: Calcd for C24H26N3O3; 404.1969; found: 404.1966.
N13-(2-Propionyloxyethyl)evodiamine (2-21). Colorless solid product 1.01 g, yield 43.0%, m.p. 205–206 °C. 1H-NMR (CDCl3) δ, ppm: 1.02 (t, J = 7.5 Hz, 3H), 2.21 (q, J = 7.5 Hz, 2H), 2.41 (s, 3H), 2.84–3.07 (m, 2H), 3.21 (td, J1 = 12.6 Hz, J2 = 3.9 Hz, 1H), 4.38–4.47 (m, 3H), 4.68–4.79 (m, 1H), 4.89–4.96 (m, 1H), 6.01 (s, 1H), 7.16–7.20 (m, 1H), 7.21–7.23 (m, 1H), 7.25–7.27 (m, 1H), 7.30–7.32 (m, 1H), 7.43–7.46 (m, 1H), 7.48–7.53 (m, 1H), 7.61 (d, J = 7.8 Hz, 1H), 8.14 (dd, J1 = 8.1 Hz, J2 = 1.5 Hz, 1H). HRMS m/z (M+H)+: Calcd for C24H26N3O3, 404.1969; found: 404.1979.
N13-(2-(Ethoxycarbonyl)ethyl)evodiamine (2-22). Colorless viscous solid product 1.36 g, yield 57.9%. 1H-NMR (CDCl3) δ, ppm: 1.21 (t, J = 7.2 Hz, 3H), 2.42 (s, 3H), 2.89–2.90 (m, 3H), 3.01–3.07 (m, 1H), 3.16–3.21 (m, 1H), 4.10 (q, J = 7.2 Hz, 2H), 4.43–4.53 (m, 1H), 4.73–4.83 (m, 1H), 4.91–4.97 (m, 1H), 6.09 (s, 1H), 7.21–7.33 (m, 4H), 7.46 (d, J = 8.4 Hz, 1H), 7.50–7.53 (m, 1H), 7.64 (d, J = 7.8 Hz, 1H), 8.18 (d, J = 7.8 Hz, 1H). 13C-NMR (CDCl3) δ, ppm: 14.1, 20.4, 34.7, 36.6, 39.3, 39.5, 60.9, 68.0, 109.6, 113.7, 119.1, 119.9, 122.9, 123.3, 124.2, 124.5, 125.9, 128.3, 129.0, 133.0, 136.9, 150.7, 164.5, 171.2. HRMS m/z (M+H)+: Calcd for C24H26N3O3, 404.1969; found 404.1969.
N13-(3-(Ethoxycarbonyl)propyl)evodiamine (2-23). Colorless solid product 1.40 g, yield 57.5%, m.p. 265–268 °C. 1H-NMR (CDCl3) δ, ppm: 1.20 (t, J = 7.2 Hz, 3H), 2.13–2.22 (m, 2H), 2.35–2.43 (m, 5H), 2.88–3.07 (m, 2H), 3.22 (td, J1 = 12.6 Hz, J2 = 3.9 Hz, 1H), 3.99–4.12 (m, 2H), 4.21–4.30 (m, 1H), 4.41–4.51 (m, 1H), 4.89–4.95 (m, 1H), 5.97 (s, 1H), 7.15–7.19 (m, 1H), 7.20–7.21 (m, 1H), 7.23–7.27 (m, 1H), 7.30–7.32 (m, 1H), 7.43–7.52 (m, 2H), 7.62 (d, J = 7.8 Hz, 1H), 8.15 (dd, J1 = 7.8 Hz, J2 = 1.5 Hz, 1H). 13C-NMR (CDCl3) δ, ppm: 14.5, 20.7, 25.6, 31.8, 36.8, 39.6, 43.3, 60.9, 68.3, 110.0, 113.6, 119.2, 119.9, 123.0, 123.3, 124.4, 125.9, 128.4, 129.1, 133.1, 137.4, 151.0, 164.7, 172.7. HRMS m/z (M+H)+: Calcd for C25H28N3O3, 418.2125; found: 418.2123.
N13-((Oxiran-2-yl)methyl)evodiamine (2-24). Yellowish solid product 0.63 g, yield 30.6%, m.p. 189–191 °C.1H-NMR (CDCl3) δ, ppm: 2.21–2.23 (m, 1H), 2.39 (s, 3H), 2.69 (t, J = 4.2 Hz, 1H), 2.83–2.93 (m, 1H), 2.99–3.05 (m, 1H), 3.16–3.21 (m, 1H), 3.23–3.27 (m, 1H), 4.43 (d, J = 3.6 Hz, 0.5 H), 4.48 (d, J = 3.6 Hz, 0.5H), 4.87–4.90 (m, 1H), 4.94 (d, J = 3.3 Hz, 1H), 6.06 (s, 1H), 7.16–7.21 (m, 2H), 7.23–7.27 (m, 1H), 7.28–7.34 (m, 1H), 7.40–7.43 (m, 1H), 7.47–7.52 (m, 1H), 7.58–7.62 (m, 1H), 8.13 (dd, J1 = 7.8 Hz, J2 = 1.5 Hz, 1H). HRMS m/z (M+H)+: Calcd for C22H22N3O2, 360.1707; found: 360.1712.
N13-(2-iso-Butyryloxyethyl)evodiamine (2-25). Viscous solid product 1.42 g, yield 56.7%. 1H-NMR (CDCl3) δ, ppm: 1.01–1.05 (m, 6H), 2.36–2.46 (m, 4H), 2.84–2.95 (m, 1H), 3.01–3.07 (m, 1H), 3.16–3.25 (m, 1H), 4.38–4.48 (m, 3H), 4.69–4.80 (m, 1H), 4.89–4.96 (m, 1H), 6.00 (s, 1H), 7.16–7.20 (m, 1H), 7.21–7.23 (m, 1H), 7.25–7.28 (m, 2H), 7.44–7.47 (m, 1H), 7.48–7.53 (m, 1H), 7.59–761 (m, 1H), 8.14 (dd, J1 = 7.8 Hz, J2 = 1.2 Hz, 1H). 13C-NMR (CDCl3) δ, ppm: 19.1, 20.7, 34.2, 36.9, 39.6, 42.8, 63.2, 68.4, 110.0, 114.0, 119.2, 120.1, 123.1, 123.5, 124.4, 124.6, 126.0, 128.6, 129.2, 133.1, 137.7, 151.0, 164.6, 176.8. HRMS m/z (M+H)+: Calcd for C25H28N3O3, 418.2125; found: 418.2122.
N13-(5-Bromopentyl)evodiamine (2-26). Yellowish solid product 1.74 g, yield 64.1%. 1H-NMR (CDCl3) δ, ppm: 1.52–1.62 (m, 2H), 1.86–1.93 (m, 4H), 2.42 (s, 3H), 2.84–2.95 (m, 1H), 3.01–3.07 (m, 1H), 3.15–3.25 (m, 1H), 3.37–3.45 (m, 2H), 4.15–4.25 (m, 1H), 4.33–4.43 (m, 1H), 4.89–4.95 (m, 1H), 5.97 (s, 1H), 7.15–7.22 (m, 2H), 7.24–7.32 (m, 2H), 7.37–7.39 (m, 1H), 7.48–7.53 (m, 1H), 7.59–7.62 (m, 1H), 8.16 (dd, J = 7.8 Hz, 1.2 Hz, 1H). 13C-NMR (CDCl3) δ, ppm: 20.8, 26.1, 29.7, 32.2, 32.7, 33.7, 39.7, 44.1, 68.4, 109.9, 113.4, 119.3, 119.8, 122.9, 123.3, 124.4, 124.5, 126.0, 128.5, 129.2, 133.1, 137.3, 151.0, 164.7. HRMS m/z (M+H)+: Calcd for C24H27BrN3O, 452.1332; found: 452.1343.
N13-(Propoxycarbonylmethyl)evodiamine (2-27). Yellowish solid product 1.65 g, yield 68.2%, m.p. 168–170 °C. 1H-NMR (CDCl3) δ, ppm: 0.88 (t, J = 7.5 Hz, 3H), 1.58–1.70 (m, 2H), 2.43 (s, 3H), 2.94–2.99 (m, 1H), 3.09 (d, J = 13.8 Hz, 1H), 3.21–3.31 (m, 1H), 4.07–4.18 (m, 2H), 4.94–5.00 (m, 2H), 5.23 (d, J = 8.7 Hz, 1H ), 5.96 (s, 1H), 7.18–7.22 (m, 2H), 7.28–7.32 (m, 3H), 7.49–7.55 (m, 1H), 7.65 (d, J = 7.5 Hz, 1H), 8.17 (dd, J1 = 7.8 Hz, J2 = 1.5 Hz,1H). 13C-NMR (CDCl3) δ, ppm: 10.3, 20.2, 21.9, 36.8, 39.3, 45.3, 67.2, 68.0, 109.1, 114.0, 119.2, 120.2, 123.2, 123.5, 124.3, 124.6, 126.0, 128.4, 129.0, 132.9, 137.8, 150.8, 164.5, 171.7. HRMS m/z (M+H)+: Calcd for C24H26N3O3, 404.1969; found: 404.1985.
N13-(4-(Ethoxycarbonyl)butyl)evodiamine (2-28). Solid product 1.89 g, yield 70.7%, m.p. 251–253 °C. 1H-NMR (CDCl3) δ, ppm: 1.14 (t, J = 7.2 Hz, 3H), 1.30–1.38 (m, 2H), 1.54–1.61 (m, 2H), 1.78 (t, J = 7.8 Hz, 2H), 2.32 (s, 3H), 2.77–2.81 (m, 1H), 2.85–2.93 (m, 1), 3.06–3.12 (m, 1H), 4.03 (q, J = 7.2 Hz, 2H), 4.23–4.33 (m, 1H), 4.73–4.83 (m, 1H ), 4.91–4.97 (m, 1H ), 6.09 (s, 1H), 7.21–7.33 (m, 4H), 7.46 (d, J = 8.4 Hz, 1H), 7.50–7.53 (m, 1H), 7.64 (d, J = 7.8 Hz, 1H), 8.18 (d, J = 7.8 Hz, 1H). 13C-NMR (CDCl3) δ, ppm: 14.1, 20.4, 34.7, 36.6, 39.3, 39.5, 60.9, 68.0, 109.6, 113.7, 119.1, 119.9, 122.9, 123.3, 124.2, 124.5, 125.9, 128.3, 129.0, 133.0, 136.9, 151.7, 164.5, 171.2. HRMS m/z (M+H)+: Calcd for C26H30N3O3, 432.2238; found: 432.2216.
N13-(5-(Ethoxycarbonyl)pentyl)evodiamine (2-29). Viscous solid product 1.59 g, yield 57.7%. 1H-NMR (CDCl3) δ, ppm: 1.21–1.28 (m, 5H), 1.71–1.75 (m, 2H), 1.88–1.1.93 (m, 2H), 2.35 (t, J = 7.5 Hz, 2H), 2.41 (s, 3H), 2.91–2.96 (m, 1H), 3.03 (d, J = 3.3 Hz, 1H), 3.07–3.22(m, 1H), 4.12 (q, J = 7.2 Hz, 2H), 4.19–4.27 (m, 1H), 4.36–4.43 (m, 1H), 4.90–4.97 (m, 1H ), 5.99 (s, 1H), 7.19–7.31 (m, 4H), 7.42 (d, J = 8.1 Hz, 1H), 7.50–7.53 (m, 1H), 7.64 (d, J = 7.8 Hz, 1H), 8.18 (dd, J1 = 8.1 Hz, J2 = 1.5 Hz, 1H). HRMS m/z (M+H)+: Calcd for C27H32N3O3, 446.2438; found 446.2440.

3.3. Synthetic Procedure for 3-1–3-3

NaH (40% oil, 7.2 mmol) was suspended in a solution of evodiamine (1, 1.82 g, 6.0 mmol) in DMF (30 mL). The mixture was stirred for 20 min, 2.6 mmol of the appropriate alkylating reagent was added into the mixture, and the rest of the protocol was as described above.
1,5-Bis-(evodiamin-N13-yl)pentane (3-1). Solid product 0.67 g, yield 38.3%, m.p. 217–219 °C. 1H-NMR (CDCl3) δ, ppm: 1.83 (s, 2H), 1.94–1.99 (m, 4H), 2.20–2.23 (m, 6H), 2.88–3.17 (m, 6H), 4.13–4.16 (m, 2H), 4.31–4.39 (m, 2H), 4.82–4.88 (m, 2H), 5.76 (s, 1.2H), 5.86 (s, 0.8H), 6.69 (s, 1.16H), 6.96 (s, 0.84), 7.18–7.29 (m, 6H), 7.31–7.46 (m, 4H), 7.64 (d, J = 8.1 Hz, 2H), 8.13 (dd, J1 = 7.8 Hz, J2 = 1.5 Hz, 2H). 13C-NMR (CDCl3) δ, ppm: 20.3, 27.5, 28.3, 36.4, 39.3, 43.6, 68.0, 109.7, 113.4, 119.2, 119.8, 122.8, 123.0, 124.1, 124.4, 125.7, 128.3, 129.0, 133.0, 137.3, 150.7, 164.4. ESI-MS, m/e 675.3 [M+H]+. Anal. Calcd for C43H42N6O2: C, 76.53; H, 6.27. Found: C, 76.56; H, 6.34.
N1,6-Bis-(evodiamin-N13-yl)hexane (3-2). Colorless solid product 0.96 g, yield 53.6%, m.p. 131–133 °C. 1H-NMR (CDCl3) δ, ppm: 1.35 (s, 4H), 1.78 (s, 4H), 2.36 (s, 6H), 2.82–2.91 (m, 2H), 2.99–3.03 (m, 2H), 3.10–3.21(m, 2H), 4.08–4.17 (m, 2H), 4.28–4.38 (m, 2H), 4.91 (dd, J1 = 12.6 Hz, J2 = 3.3 Hz, 2H), 5.92 (s, 2H), 7.12–7.18 (m, 4H), 7.20–7.31 (m, 6H), 7.44–7.49 (m, 2H), 7.60 (d, J = 7.8 Hz, 2H), 8.15 (d, J = 7.8 Hz, 2H). 13C-NMR (CDCl3) δ, ppm: 20.4, 27.0, 30.2, 36.5, 39.3, 43.7, 68.0, 109.7, 113.1, 119.1, 119.6, 122.6, 123.0, 124.1, 124.2, 125.7, 128.2, 129.0, 132.9, 137.1, 150.9, 164.5. HRMS m/z (M+H)+: Calcd for C44H45N6O2, 689.3599; found: 689.3608.
N1,2-Bis-((2-evodiamin-N13-yl)ethyoxy)ethane (3-3). Solid product 0.86 g, yield 46.0%, m.p. 143–145 °C. 1H-NMR (CDCl3) δ, ppm: 2.30 (s, 6H), 2.78–2.93 (m, 4H), 3.05–3.16 (m, 2H), 3.18–3.19 (m, 4H), 3.44–3.52 (m, 4H), 4.07–4.13 (m, 2H), 4.45–4.52 (m, 2H), 4.76–4.82 (m, 2H), 5.97 (s, 2H), 7.08–7.12 (m, 6H), 7.17–7.23 (m, 4H), 7.37–7.39 (m, 2H), 7.51 (d, J = 7.8 Hz, 2H), 8.05 (d, J = 7.8 Hz, 2H). 13C-NMR (CDCl3) δ, ppm: 20.3, 36.5, 39.3, 43.7, 67.9, 70.0, 70.8, 109.8, 113.1, 118.9, 119.7, 122.5, 122.6, 123.1, 124.1, 125.8, 128.9, 129.0, 132.9, 137.2, 150.9, 164.6. HRMS m/z (M+H)+: Calcd for C44H45N6O4, 721.3497; found: 721.3489.

3.4. Synthetic Procedure for 4-1, 4-2, 5, 6, 6-1 and 6-2

NaOH–H2O (20%, 10.0 mmol) was added into a solution of 2.0 mmol of the appropriate compound 2-19 or 2-20 and 2-23 in ethanol (30 mL) and the mixture was heated to reflux for 3–4 h, while monitored by TLC. The mixture was neutralized with 20% HCl, the ethanol was removed under reduced pressure. The residue was extracted with EtOAc, and after the EtOAc was removed under reduced pressure, the crude product was purified by column chromatography to afford the pure target compounds.
N13-(2-Hyroxyethyl)evodiamine (4-1). Colorless solid product 0.43 g, yield 62.0%, m.p. 166–168 °C. 1H-NMR (DMSO-d6) δ, ppm: 2.38 (s, 3H), 2.71–2.83 (m, 1H), 2.95–3.02 (m, 1H), 3.03–3.21 (m, 1H), 3.64–3.69 (m, 2H), 4.30–4.43 (m, 2H), 4.66 (dd, J1 = 12.3 Hz, J2 = 3.3 Hz, 1H), 4.87 (t, J = 5.4 Hz, 1H), 6.18 (s, 1H), 7.04–7.09 (m, 1H), 7.16–7.22 (m, 2H), 7.30 (d, J = 8.1 Hz, 1H), 7.50–7.57 (m, 3H), 7.91 (dd, J1 = 8.4 Hz, J2 = 1.2 Hz, 1H). ESI-MS, m/z 348.2 [M+H]+. Anal. Calcd for C21H21N3O2: C, 72.60; H, 6.09. Found: C, 72.56; H, 6.17.
N13-(3-Hyroxypropyl)evodiamine (4-2). Yellowish solid product 0.51 g, yield 70.6%, m.p. 82–84 °C. 1H-NMR (CDCl3) δ, ppm: 2.10–2.16 (s, 2H), 2.45 (s, 3H), 2.90–2.94 (m, 1H), 3.03–3.07 (m, 2H), 3.13–3.17 (m, 1H), 3.66 (d, J = 5.1 Hz, 2H), 4.32–4.36 (m, 1H), 4.45–4.52 (m, 1H), 4.89–4.93 (m, 1H), 6.08 (s, 1H), 7.21–7.34 (m, 4H), 7.48–7.51 (m, 2H), 7.62–7.66 (m, 1H), 8.13 (d, J = 4.2 Hz, 1H). 13C-NMR (CDCl3) δ, ppm: 20.4, 32.4, 36.4, 39.5, 40.3, 59.0, 68.1, 110.2, 113.6, 119.1, 119.8, 122.8, 123.1, 124.1, 124.8, 125.8, 128.5, 129.0, 133.1, 137.4, 151.0, 164.5. HRMS m/z (M+H)+: Calcd for C22H24N3O2, 362.1863; found: 362.1876.
4-(Evodiamin-N13-yl)butyric acid (5). Colorless solid product 0.56 g, m.p. 234 °C (decomposed) yield 69.5%. 1H-NMR (DMSO-d6) δ, ppm: 1.97–2.01 (m, 2H), 2.29 (t, J = 7.2 Hz, 2H), 2.36 (s, 3H), 2.79–2.82 (m, 1H), 3.00–3.07 (m, 1H), 3.10–3.14 (m, 1H), 4.24–4.31 (m, 2H), 4.68 (dd, J1 =12.6 Hz, J2 = 3.9 Hz, 1H), 6.15 (s, 1H), 7.08–7.13 (m, 1H), 7.20–7.26 (m, 2H), 7.32 (d, J = 7.8 Hz, 1H), 7.53–7.61 (m, 3H), 7.94 (d, J = 6.6 Hz, 1H), 12.2 (s, 1H, –CO2H). 13C-NMR (CDCl3) δ, ppm: 19.8, 24.8, 30.8, 36.0, 42.6, 57.2, 67.1, 110.1, 112.2, 118.8, 119.2, 122.2, 123.0, 123.5, 125.3, 128.0, 128.4, 132.9, 136.8 150.6, 163.6, 174.0. HRMS m/z (M-H)-: Calcd for C23H22N3O3, 388.1667; found: 388.1670.
2-(Evodiamin-N13-yl)acetaldehyde (6). This compound was obtained by the hydrolysis of 9-(2,2-diethoxyethyl)evodiamine (2-18). Into a solution of 2-18 (1.26 g, 3.0 mmol) in ethanol (20 mL) was added 10% hydrochloric acid (10 mL), and the mixture was stirred for 4-5 h at room temperature, while monitored by TLC. After the reaction was complete, the mixture was neutralized with 10% NaOH, and the ethanol was evaporated under reduced pressure. The product precipitated when the mixture was cooled to room temperature, and the product 6 (0.35 g) was collected by filtration. Yield 33.8%, m.p. 149–151 °C. 1H-NMR (CDCl3) δ, ppm: 2.47 (s, 3H), 2.89–3.01 (m, 1H), 3.03–3.10 (m, 1H), 3.31–3.38 (m, 1H), 4.90–4.99 (m, 2H), 5.12–5.21 (m, 1H), 5.95 (s,1H), 7.15–7.20 (m, 1H), 7.21–7.25 (m, 2H), 7.27–7.32 (m, 1H), 7.32–7.37 (m, 1H), 7.42–7.48 (m, 1H), 7.49–7.56 (m, 1H), 7.62 (t, J = 6.6 Hz, 1H), 9.88 (s, 1H). HRMS m/z (M+H)+: Calcd for C21H20N3O2, 346.1550; found 346.1549.
2-(Evodiamin-N13-yl)acetaldehyde oxime (6-1). Compound 6-1 was obtained by the condensation reaction of 6 with hydroxylamine hydrochloride. Into a solution of 6 (0.52 g, 1.5 mmol) in absolute ethyl alcohol (20 mL) was added hydroxylamine hydrochloride (0.21 g, 3.0 mmol) and triethylamine (0.61 g, 6 mmol) and the mixture was stirred for 4-5 h at room temperature, while monitored by TLC. After the reaction was complete the ethanol was evaporated under reduced pressure. The product 6-1 (0.30 g) was obtained by filtration, yield 27.8%, m.p. 201–203 °C. 1H-NMR (CDCl3) δ, ppm: 2.42 (s, 3H), 2.87–2.98 (m, 1H), 3.01–3.10 (m, 1H), 3.16–3.27 (m, 1H), 4.89–4.98 (m, 2H), 5.11–5.20 (m, 1H), 5.33–5.40 (m, 1H, -OH), 5.95 (s, 0.48H), 5.98 (s, 0.52H), 7.15–7.20 (m, 1H), 7.21–7.25 (m, 2H), 7.27–7.32 (m, 1H), 7.32–7.37 (m, 1H), 7.42–7.48 (m, 1H), 7.49–7.56 (m, 1H), 7.62 (t, J = 6.6 Hz, 1H), 8.14 (d, J = 7.8 Hz, 1H). HRMS m/z (M+H)+: Calculated for C21H21N4O2, 361.1659; found 361.1670.
2-(Evodiamin-N13-yl)acetaldehyde O-methyl oxime (6-2). Compound 6-2 was synthesized as 6-1, yield 57.0%, m.p. 216 °C (decomposed). 1H-NMR (CDCl3) δ, ppm: 2.41 (s, 3H), 2.89–2.97 (m, 1H), 3.02–3.07 (m, 1H), 3.17–3.27 (m, 1H), 3.86 (s, 2H, -OCH3), 3.99 (s, 1H, -OCH3), 4.88–4.92 (m, 1H), 4.94–4.96 (m, 1H), 5.04–5.14 (m, 1H), 5.93 (s, 0.34H), 5.98 (s, 0.66H), 7.18–7.23 (m, 2H), 7.24–7.26 (m, 1H), 7.28–7.34 (m, 2H), 7.44–7.48 (m, 1H), 7.48–7.53 (m, 1H), 7.59–7.64 (m, 1H), 8.15 (d, J = 0.9 Hz, 1H). ESI-MS, m/e 375.2 [M+H]+. Anal. Calcd for C22H22N4O2: C, 70.57; H, 5.92. Found: C, 70.60; H, 6.07.

3.5. Solubility of N13-Substituted Evodiamine Derivatives in SGF and SIF Solutions

SGF and SIF solutions were prepared as described in the United States Pharmacopoeia [31], and the solubilities of N13-substituted evodiamine derivatives in SGF and SIF solutions were determined by the reported method [32,33,34,35] with slight modifications.

3.6. Inhibitory Effects of N13-Substituted Evodiamine Derivatives toward Six Cultured Human Cancer Cell Lines

The growth inhibition effects of the thirty N13-substituted evodiamine derivates on human prostate cancer cell lines (DU-145 and PC-3), lung cancer cell line (H460), breast cancer cell line (MCF-7), colon cancer cell line (HCT-5) and glioblastoma cell lines (SF-268) were determined by MTT assay with evodiamine as positive control.

3.7. Apoptosis of Human Cancer Cells Induced by 2-2, 2-3, 2-26 and 3-2

Apoptosis of human cancer cell lines (MCF-7, NCl-H460 and HCT-15) induced by 2-2, 2-3, 2-16 and 3-2 was determined by flow cytometry analysis using the Annexin V-FITC/PI Apoptosis Kit. Cancer cells were plated at a density of 3 × 105 cells per well in 6-well plates, incubated overnight and then treated with different concentrations of test compounds at their respective IC50 levels (predetermined by the MTT cytotoxicity assays) for 48 h. Staining was performed according to the manufacturer’s instructions. Stained cells were analyzed by a FACSCalibur flow cytometer (Becton Dickinson) using the CellQuest™ software. The percentages of early apoptosis were calculated by Annexin V-positivity and PI-negativity, while that of late apoptosis were determined by Annexin V-positivity and PI-positivity.

4. Conclusions

In conclusion, we have synthesized thirty-eight evodiamine derivates with different substituents at the N13-position and preliminarily evaluated their inhibitory activities against six cancer cell lines and their solubility in SGF and SIF. It could be concluded that: (1) the appropriate substitution on the N13-position of evodiamine made some derivatives (compounds 2-2, 2-3, 2-9, 2-16, 3-2) show more antitumor potency and broadened antitumor spectra. Among these, compound 2-16 displayed the highest antitumor activity and a broader spectrum, with IC50 values of less than 2 µM; (2) their solubility was obviously improved; (3) compounds 2-3, 2-16 and 3-2 had a significant impact inducing apoptosis in some cancer cell lines. Meantime, the preliminary structure-activity relationships of these derivatives were discussed. Further investigation of these derivatives, including more screening of anticancer activity and determination of their mechanisms of action against tumor cell lines are ongoing.

Acknowledgments

The authors acknowledge the financial support of the National Science Foundation of China (21272287).

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Yu, H.; Jin, H.; Gong, W.; Wang, Z.; Liang, H. Pharmacological actions of multi-target-directed evodiamine. Molecules 2013, 18, 1826–1843. [Google Scholar]
  2. Chen, B.-Y.; Qiu, T. Traditional Chinese Medicine Composition for Treating Greasy Food Regurgitation [Machine Translation]. Patent CN 103301272 A, 18 September 2012. [Google Scholar]
  3. Juchi, S.; Uchida, Y. A Hair Nourishing and Hair Growth Promoting Food Prepared from Evodia rutaecarpa benth (Evodiae fructus) or Evodia rutaecarpa benth var Officinalis Huang Belonging to Rutaceae. Patent JP 61001619, 1986. [Google Scholar]
  4. Jiang, J.; Hu, C. Evodiamine: A novel anti-cancer alkaloid from evodia rutaecarpa. Molecules 2009, 14, 1852–1859. [Google Scholar] [CrossRef]
  5. Yang, J.; Cai, X.; Lu, W.; Hu, C.; Xu, X.; Yu, Q.; Cao, P. Evodiamine inhibits STAT3 signaling by inducing phosphatase shatterproof I in hepatocellular carcinoma cells. Cancer Lett. 2013, 328, 243–251. [Google Scholar] [CrossRef]
  6. Wu, J.-Y.; Chang, M.-C.; Chen, C.-S.; Lin, H.-C.; Tsai, H.-P.; Yang, C.-C.; Yang, C.-H.; Lin, C.-M. Topoisomerase I inhibitor evodiamine acts as an antibacterial agent against drug-resistant Klebsiella pneumoniae. Planta Med. 2013, 79, 27–29. [Google Scholar]
  7. Wang, K.-L.; Hsia, S.-M.; Yeh, J.-Y.; Cheng, S.-C.; Wang, P.S.; Wang, S.-W. Anti-proliferative effects of evodiamine on human breast cancer cells. PLoS One 2013, 8, e67297. [Google Scholar]
  8. Li-Weber, M. Targeting apoptosis pathways in cancer by Chinese medicine. Cancer Lett. 2013, 332, 304–312. [Google Scholar] [CrossRef]
  9. Wei, W.-T.; Chen, H.; Wang, Z.-H.; Ni, Z.-L.; Liu, H.-B.; Tong, H.-F.; Guo, H.-C.; Liu, D.-L.; Lin, S.-Z. Enhanced antitumor efficacy of gemcitabine by evodiamine on pancreatic cancer via regulating PI3K/Akt pathway. Int. J. Biol. Sci. 2012, 8, 1–14. [Google Scholar]
  10. Wang, Z.; Sun, L.; Yu, H.; Zhang, Y.; Gong, W.; Jin, H.; Zhang, L.; Liang, H. Binding mode prediction of evodiamine within vanilloid receptor TRPV1. Int. J. Biol. Sci. 2012, 13, 8958–8969. [Google Scholar]
  11. Rasul, A.; Yu, B.; Zhong, L.; Khan, M.; Yang, H.; Ma, T. Cytotoxic effect of evodiamine in SGC-7901 human gastric adenocarcinoma cells via simultaneous induction of apoptosis and autophagy. Oncol. Rep. 2012, 27, 1481–1487. [Google Scholar]
  12. Pan, X.; Hartley, J.M.; Hartley, J.A.; White, K.N.; Wang, Z.; Bligh, S.W. A. Evodiamine, a dual catalytic inhibitor of type I and II topoisomerases, exhibits enhanced inhibition against camptothecin resistant cells. Phytomedicine 2012, 19, 618–624. [Google Scholar] [CrossRef]
  13. Dong, G.; Sheng, C.; Wang, S.; Miao, Z.; Yao, J.; Zhang, W. Selection of evodiamine as a novel topoisomerase I inhibitor by structure-based virtual screening and hit optimization of evodiamine derivatives as antitumor agents. J. Med. Chem. 2010, 53, 7521–7531. [Google Scholar] [CrossRef]
  14. Zhang, C.; Fan, X.; Xu, X.; Yang, X.; Wang, X.; Liang, H.-P. Evodiamine induces caspase-dependent apoptosis and S phase arrest in human colon loVo cells. Anti-Cancer Drugs 2010, 21, 766–776. [Google Scholar] [CrossRef]
  15. Wang, C.; Li, S.; Wang, M. Evodiamine-induced human melanoma A375-S2 cell death was mediated by PI3K/Akt/caspase and Fas-L/NF-κB signaling pathways and augmented by ubiquitin-proteasome inhibition. Toxicol. In Vitro 2010, 24, 898–904. [Google Scholar] [CrossRef]
  16. Dong, G.; Wang, S.; Miao, Z.; Yao, J.; Zhang, Y.; Guo, Z.; Zhang, W.; Sheng, C. New tricks for an old natural product: Discovery of highly potent evodiamine derivatives as novel antitumor agents by systemic structure-activity relationship analysis and biological evaluations. J. Med. Chem. 2012, 55, 7593–7613. [Google Scholar]
  17. Chen, M.-C.; Yu, C.-H.; Wang, S.-W.; Pu, H.-F.; Kan, S.-F.; Lin, L.-C.; Chi, C.-W.; Ho, L.L.-T.; Lee, C.-H.; Wang, P.S. Anti-proliferative effects of evodiamine on human thyroid cancer cell line ARO. J. Cell. Biochem. 2010, 110, 1495–1503. [Google Scholar] [CrossRef]
  18. Yang, Z.-G.; Chen, A.Q.; Liu, B. Antiproliferation and apoptosis induced by evodiamine in human Colorectal carcinoma cells (COLO-205). Chem. Biodivers. 2009, 6, 924–933. [Google Scholar] [CrossRef]
  19. Wang, T.; Wang, Y.; Yamashita, H. Evodiamine inhibits adipogenesis via the EGFR-PKCalpha-ERK signaling pathway. FEBS Lett. 2009, 583, 3655–3659. [Google Scholar] [CrossRef]
  20. Chan, A.L.F.; Chang, W.-S.; Chen, L.-M.; Lee, C.-M.; Chen, C.-E.; Lin, C.-M.; Hwang, J.-L. Evodiamine stabilizes topoisomerase I-DNA cleavable complex to inhibit topoisomerase I activity. Molecules 2009, 14, 1342–1352. [Google Scholar] [CrossRef]
  21. Kan, S.-F.; Yu, C.-H.; Pu, H.-F.; Hsu, J.-M.; Chen, M.-J.; Wang, P.S. Anti-proliferative effects of evodiamine on human prostate cancer cell lines DU145 and PC3. J. Cell. Biochem. 2007, 101, 44–56. [Google Scholar] [CrossRef]
  22. Shyu, K.-G.; Lin, S.; Lee, C.-C.; Chen, E.; Lin, L.-C.; Wang, B.-W.; Tsai, S.-C. Evodiamine inhibits in vitro angiogenesis: Implication for antitumorgenicity. Life Sci. 2006, 78, 2234–2243. [Google Scholar] [CrossRef]
  23. Liao, C.H.; Pan, S.L.; Guh, J.H.; Chang, Y.L.; Pai, H.C.; Lin, C.H.; Teng, C.M. Antitumor mechanism of evodiamine, a constituent from Chinese herb evodiae fructus, in human multiple-drug resistant breast cancer NCI/ADR-RES cells in vitro and in vivo. Carcinogenesis 2005, 26, 968–975. [Google Scholar]
  24. Shi, B.; Cao, R.; Fan, W.; Guo, L.; Ma, Q.; Chen, X.; Zhang, G.; Qiu, L.; Song, H. Design, synthesis and in vitro and in vivo antitumor activities of novel bivalent β-carbolines. Eur. J. Med. Chem. 2013, 60, 10–22. [Google Scholar] [CrossRef]
  25. Huang, Y.; Cui, J.; Zhong, Z.; Gan, C.; Zhang, W.; Song, H. Synthesis and cytotoxicity of 17α-aza-D-homo-androster-17-one derivatives. Bioorg. Med. Chem. Lett. 2011, 21, 3641–3643. [Google Scholar] [CrossRef]
  26. Chen, Z.; Cao, R.; Shi, B.; Guo, L.; Sun, J.; Ma, Q.; Fan, W.; Song, H. Synthesis and biological evaluation of 1,9-disubstituted β-carbolines as potent DNA intercalating and cytotoxic agents. Eur. J. Med. Chem. 2011, 46, 5127–5137. [Google Scholar] [CrossRef]
  27. Ma, C.; Cao, R.; Shi, B.; Zhou, X.; Ma, Q.; Sun, J.; Guo, L.; Yi, W.; Chen, Z.; Song, H. Synthesis and cytotoxic evaluation of 1-carboxamide and 1-amino side chain substituted β-carbolines. Eur. J. Med. Chem. 2010, 45, 5513–5519. [Google Scholar] [CrossRef]
  28. Chen, Z.; Cao, R.; Shi, B.; Yi, W.; Yu, L.; Song, H.; Ren, Z.; Peng, W. Synthesis of novel β-carbolines with efficient DNA-binding capacity and potent cytotoxicity. Bioorg. Med. Chem. Lett. 2010, 20, 3876–3879. [Google Scholar] [CrossRef]
  29. Huang, Y.; Cui, J.; Jia, L.; Gan, C.; Song, H.; Zeng, C.; Zhou, A. Synthesis and evaluation of some 17-acetamidoandrostane and N,N-dimethyl-7-deoxycholic amide derivatives as cytotoxic agents: Structure/activity studies. Molecules 2013, 18, 7436–7447. [Google Scholar] [CrossRef]
  30. ChemBioDraw Ultra 11.0. PerkinElmer: Waltham, MA, USA, 2013. Available online: http://www.cambridgesoft.com (accessed on 21 November 2013).
  31. Simulated Gastric Fluid and SimulatIntestinal Fluid, TS. In The United States Pharmacopeia 23, the National Formulary 18; The United States Pharmacopeial Convention, Inc.: Rockville, MD, USA, 1995; p. 2053.
  32. Mondal, S.K.; Mondal, N.B.; Banerjee, S.; Mazumder, U.K. Determination of drug-like properties of a novel antileishmanial compound: In vitro absorption, distribution, metabolism, and excretion studies. Indian J. Pharmacol. 2009, 41, 176–181. [Google Scholar] [CrossRef]
  33. Rawat, J.; Jain, P.K.; Ravichandran, V.; Agrawal, R.K. Synthesis and evaluation of mutual prodrugs of isoniazid, p-amino salicylic acid and ethambutol. ARKIVOC 2007, 1, 105–118. [Google Scholar]
  34. Lokhande, P.; Gite, S.; Sakarkar, D.M. Dissolution method developmeng for gastro retentive controlled releave cephalaxin tablet. Int. Res. J. Pharm. 2012, 3, 244–247. [Google Scholar]
  35. Ahmed, S.A.J.; Ahmed, A. HFormulation and evaluation of Piroxicam liquisolid compacts. Int. J. Pharm. Pharm. Sci. 2013, 5, 132–141. [Google Scholar]
  • Sample Availability: Samples of the compounds 1, 2-1, 2-2, 2-5, 2-6, 2-13 and 3-2, are available from the authors.

Share and Cite

MDPI and ACS Style

Song, S.; Chen, Z.; Li, S.; Huang, Y.; Wan, Y.; Song, H. Design, Synthesis and Evaluation of N13-Substituted Evodiamine Derivatives against Human Cancer Cell Lines. Molecules 2013, 18, 15750-15768. https://doi.org/10.3390/molecules181215750

AMA Style

Song S, Chen Z, Li S, Huang Y, Wan Y, Song H. Design, Synthesis and Evaluation of N13-Substituted Evodiamine Derivatives against Human Cancer Cell Lines. Molecules. 2013; 18(12):15750-15768. https://doi.org/10.3390/molecules181215750

Chicago/Turabian Style

Song, Senchuan, Zhiyong Chen, Shaoxue Li, Yanmin Huang, Yiqian Wan, and Huacan Song. 2013. "Design, Synthesis and Evaluation of N13-Substituted Evodiamine Derivatives against Human Cancer Cell Lines" Molecules 18, no. 12: 15750-15768. https://doi.org/10.3390/molecules181215750

Article Metrics

Back to TopTop